A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV
Status:
Completed
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether teduglutide can repair a "leaky"
gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other
materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to
inflammatory changes and leakiness of the gut. These changes or conditions may increase the
risk of developing heart and blood vessel disease. The investigators believe teduglutide can
help repair the gut barrier in people with HIV, leading to a decrease in inflammation and
plaque in the blood vessels of the heart.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) Ragon Institute of MGH, MIT and Harvard